Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

H2020: Búsqueda de socios en oncología y administración de fármacos para unirse a una red de modelado y simulación numérica de administración de medicamentos contra el cáncer de hígado

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDFR20161104001
Publicado:
21/11/2016
Caducidad:
21/11/2017
Resumen:
Un consorcio francés está preparando una propuesta para la convocatoria de Medicina Personalizada del programa Horizonte 2020 (SC1-PM-16-2017: Ensayos in-silico para desarrollar y evaluar productos biomédicos). El objetivo del proyecto es ofrecer un nuevo modelo digital y fisiológico en 3D de perfusión hepática capaz de simular la inyección de un medicamento y su impacto en los tejidos sanos y lesiones hepáticas. El equipo de investigación busca socios en los sectores público y privado especializados en oncología y administración de fármacos. La fecha límite de la convocatoria es el 14 de marzo de 2017 y el plazo para presentar expresiones de interés finaliza el 27 de enero.

Details

Tittle:
H2020: Partners on oncology and drug delivery needed to join a network on numerical modeling and simulation of anticancer drug delivery in liver
Summary:
A French-based consortium is preparing a proposal for the Horizon 2020 Personalised Medicine programme; Call: SC1-PM-16-2017
In-silico trials for developing and assessing biomedical products.The project is to propose a novel 3D digital and physiological model of the liver perfusion, capable of simulating the injection of a drug and its impact upon healthy tissues and hepatic lesions. The research team is looking for private or public partners focused on oncology and drug delivery.
Description:
The development of in-silico trials is an international scale challenge. The European Commission strongly promotes reduction of animal testing and human trials, as evidenced by several Horizon 2020 calls in Health Societal challenge.
A French university is building a consortium to propose a novel 3-dimension (3D) digital and physiological model of the liver perfusion. This model, diffused as open-source software will represent the morphology and physiology of human liver and simulate the blood flow within the vessels and other surrounding tissues. The aim is to test in-silico the injection of (new) drugs for the treatment of hepatic diseases. This will help medical doctors to plan protocols faster and better, as they will benefit from a computerized prediction of the effect of one or several drugs on a patient, before employing it practically.
The project requires a high multi-disciplinarity including:
- ICT : computer vision, medical image processing, digital geometry.
- Simulation of patients variabilities, breathing, deformable organs (lungs for example), fluids (blood), tubular solids (vessels), porous environment (liver parenchyma).
- Medicine: clinical practice, interventional radiology, hepatology, hepatic surgery.
- Chemistry, Physiology: assessment of drug action, developing new drugs, for liver and hepatic tumors.

The consortium is already composed of academic research teams, hospitals and private company, representing four European Union countries. The coordinator is a French university in the field of Innovative medical imaging.
The consortium is looking for research and private partners specialized in:
- (bio-)chemistry, physiology, pharmacology or related fields exploited for the liver.
- chemistry or pharmacology of drug delivery
- development of novel and potent drug candidates

The project is being prepared for the H2020: SC1-PM-16-2017 call which has a deadline of March 14th.
The deadline for expressions of interest is January 27th

Advantages and Innovations:
By combining skills in medicine, computer vision, mathematics, geometry, simulation and computer science, the consortium proposes challenging research for liver cancer treatment.
The proposed model is expected to allow a low-cost and repeatable experiment and act as a supporting tool design to evaluate the effectiveness of a drug therapy.

The main goal is the translation of research from animal models to humans in the development of 3D-model for relevant clinical trials and personalized medicine.
Stage of Development:
Project in negotiations - urgent
IPR Status:
Secret Know-how

Partner sought

Partner Sought:
Type of partners: research and academic institutions and private companies Specific area: - (bio-)chemistry, physiology, pharmacology, oncology or related fields exploited for the liver. - chemistry or pharmacology of drug delivery - development of novel and potent drug candidates
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Dissemination

Programme-call

Anticipated Project Budget:
6 000 000 euros
Coordinator Required:
No
Deadline for Call:
14/03/2017
Project Duration:
0